CRANBURY, N.J., March 3, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the appointment of Jay A. Barth, MD as Chief Medical Officer, effective today. Dr. Barth brings to Amicus more than 15 years of experience in drug development, clinical research and medical affairs. In his role as Chief Medical Officer, he will be responsible for all clinical development activities as well as regulatory affairs. The Company also announced the promotion of Bradley L. Campbell from Chief Business Officer to Chief Operating Officer, effective December 2013. Both Dr. Barth and Mr. Campbell report to John F. Crowley, Chairman and Chief Executive Officer of Amicus.
Mr. Crowley stated, "I am thrilled to welcome Dr. Jay Barth to our team at Amicus. Jay is the ideal person to lead our clinical and regulatory teams in the execution of our 3-in-3 strategy to advance three next-generation ERTs into the clinic over the next three years. His direct experience in clinical development, medical affairs and regulatory strategy within the rare diseases will be extremely valuable to Amicus. I would also like to congratulate Bradley Campbell on his promotion to Chief Operating Officer, as he assumes a leadership role in research and development while continuing to lead several other important Amicus teams including program management, business development, technical operations and patient advocacy. Brad will continue to be a key leader at Amicus."
Prior joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics, Inc. from 2009 to 2014. He most recently served as PTC's Senior Vice President, Clinical Development. In this role he led the clinical team and oversaw all global clinical development programs, focusing on rare diseases including Duchenne Muscular Dystrophy and Cystic Fibrosis. He also worked with PTC's regulatory affairs team to develop U.S. and European regulatory strategy, communicate with regulatory agencies, and prepare marketing applications for submission. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc.